Balaha, Mohamed, Alahmari, Abdullah, Kandeel, Samah, Balaha, Marwa. (1401). Vinpocetine’s immunomodulating, anti-oxidant, anti-inflammatory, ant-ifibrotic, and PDE inhibiting potencies ameliorate bleomycin-induced pulmonary fibrosis. , 26(1), 13-22. doi: 10.22038/ijbms.2022.64175.14130
Mohamed Balaha; Abdullah Alahmari; Samah Kandeel; Marwa Balaha. "Vinpocetine’s immunomodulating, anti-oxidant, anti-inflammatory, ant-ifibrotic, and PDE inhibiting potencies ameliorate bleomycin-induced pulmonary fibrosis". , 26, 1, 1401, 13-22. doi: 10.22038/ijbms.2022.64175.14130
Balaha, Mohamed, Alahmari, Abdullah, Kandeel, Samah, Balaha, Marwa. (1401). 'Vinpocetine’s immunomodulating, anti-oxidant, anti-inflammatory, ant-ifibrotic, and PDE inhibiting potencies ameliorate bleomycin-induced pulmonary fibrosis', , 26(1), pp. 13-22. doi: 10.22038/ijbms.2022.64175.14130
Balaha, Mohamed, Alahmari, Abdullah, Kandeel, Samah, Balaha, Marwa. Vinpocetine’s immunomodulating, anti-oxidant, anti-inflammatory, ant-ifibrotic, and PDE inhibiting potencies ameliorate bleomycin-induced pulmonary fibrosis. , 1401; 26(1): 13-22. doi: 10.22038/ijbms.2022.64175.14130

Vinpocetine’s immunomodulating, anti-oxidant, anti-inflammatory, ant-ifibrotic, and PDE inhibiting potencies ameliorate bleomycin-induced pulmonary fibrosis

Iranian Journal of Basic Medical Sciences
مقاله 3، دوره 26، شماره 1، فروردین 2023، صفحه 13-22    اصل مقاله (3.14 M)
نوع مقاله: Original Article
شناسه دیجیتال (DOI): 10.22038/ijbms.2022.64175.14130
نویسندگان
Mohamed Balaha* 1، 2؛ Abdullah Alahmari1؛ Samah Kandeel3؛ Marwa Balaha4، 5
1Clinical Pharmacy Department, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia
2Pharmacology Department, Faculty of Medicine, Tanta University, El-Gish Street, Postal No. 31527, Tanta, Egypt
3Histology Department, Faculty of Medicine, Tanta University, El-Gish Street, Postal No. 31527 Tanta, Egypt
4Department of Pharmacy, University G. d’Annunzio, Chieti-Pescara, Italy
5Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Postal No. 33516, Kafr El Sheikh, Egypt
چکیده
Objective(s): Pulmonary fibrosis (PF) is a global health problem with a high economic burden. Intratracheal administration of bleomycin is the best model that resembles the pathogenesis of PF in humans. Recently, vinpocetine proved to have neuroprotective, cardioprotective, hepatoprotective, anti-aging, and antifibrotic effects through its anti-oxidant, immunomodulating, and anti-inflammatory activities. The present study investigated the antifibrotic potentiality of vinpocetine in a rat model of PF induced by intratracheal bleomycin administration. 
Materials and Methods: PF induced by a single intratracheal instillation of 5 mg/kg bleomycin in nine-week-old Wister rats. Oral vinpocetine was used at doses of 5, 10, or 20 mg/kg to treat PF for 21 days immediately after the bleomycin instillation. 
Results: Vinpocetine dose-dependently ameliorates PF induced by bleomycin administration since vinpocetine effectively restored the normal body weight gain rates, pulmonary architecture, and collagen fiber distribution and suppressed the elevated BALF cell count, lymphocytes and neutrophils percentage, BALF, IL-6, TNF-α, and TGF-β1 levels and LDH activity, lung tissue MDA level, PDE activity, hydroxyproline content, immunohistochemical expression of α-SMA and CD68 positive macrophage, and fibrosis score. Meanwhile, it efficiently augmented the reduced BALF macrophage percentage, IL-10 level, lung tissue GSH level, CAT, and SOD activities. 
Conclusion: Vinpocetine may propose a new promising agent to manage PF.
کلیدواژه‌ها
Antifibrotic؛ Anti-inflammatory؛ Anti-oxidant؛ Pulmonary fibrosis؛ PDE؛ Vinpocetine
مراجع
آمار
تعداد مشاهده مقاله: 1,222
تعداد دریافت فایل اصل مقاله: 902
دانشگاه علوم پزشکی مشهد
آمار
تعداد نشریات29
تعداد شماره‌ها2,319
تعداد مقالات24,806
تعداد مشاهده مقاله82,210,125
تعداد دریافت فایل اصل مقاله45,434,567